ID   SKOV3/TR
AC   CVCL_HF69
DR   cancercelllines; CVCL_HF69
DR   Wikidata; Q54954771
RX   PubMed=25815442;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0532 ! SK-OV-3
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 15
//
RX   PubMed=25815442; DOI=10.3892/mmr.2015.3542;
RA   Lee C.;
RT   "Overexpression of Tyro3 receptor tyrosine kinase leads to the
RT   acquisition of taxol resistance in ovarian cancer cells.";
RL   Mol. Med. Rep. 12:1485-1492(2015).
//